Cerevance

Edit info

Founded: 2016

Location: Boston, MA

Employee range: 11 - 50

Clinical stage: Clin2

Therapy area: Parkinson's

Drug types: NEU, PSY

Lead product: CVN424

Funding: $51M B Feb 2023; $20M B Jul 2020; $45M B Apr 2020; $36M A Dec 2016

Investors: Gates Frontier, Dementia Discovery Fund, Foresite Capital, GV, Lightstone Ventures, Takeda Ventures, UPMC Enterprises, Dolby Family Ventures

cerevance.com

linkedin.com

job board

Drug notes:

CVN766 Clin1 schizophrenia; CVN-293 Clin0 ALS, Alzheimer's; CVN398 RD/Clin0 Parkinson's; 3+ undisclosed programs RD Parkinson's, Alzheimer's, undisclosed

About:

Cerevance uses their Nuclear Enriched Transcript Sort sequencing (NETSseq) platform and machine learning to discover the next generation of central nervous system disease treatments. They advertise to have one of the world’s largest proprietary databases of brain tissue with about sixty brain cell types and 14,000 tissue samples. Cerevance is a Boston-based biotech founded in 2016.

Jobs:

Main

Contact: recruit@workinbiotech.com